MIRA PHARMACEUTICALS, INC.
For the period ended Jun 30, 2026. Filed Aug 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 12, 2026
MIRA$0.62+0.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows (unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
| Six Months Ended June 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities | ||
| Net loss | $(2,358,686) | $(3,321,491) |
| Adjustments to reconcile net loss to net cash used in operations | ||
| Stock-based compensation expense | 129,466 | 1,364,378 |
| Loss from equity method investment | 179,126 | — |
| Change in operating assets and liabilities: | ||
| Prepaid expenses | (26,140) | (47,674) |
| Trade accounts payable and accrued expenses | (88,380) | (424,891) |
| Accrued compensation – related party | (242,258) | — |
| Net cash used in operating activities | (2,406,872) | (2,429,678) |
| Financing activities: | ||
| Repayment of advance payable to related party | (330,607) | |
| Offering costs | — | (21,480) |
| Proceeds from ATM equity offering | — | 348,702 |
| Net cash (used) provided by financing activities | (330,607) | 327,222 |
| Net decrease in cash | (2,737,479) | (2,102,456) |
| Cash, beginning of period | 6,346,921 | 2,832,931 |
| Cash, end of period | $3,609,442 | $730,475 |
| Supplemental disclosure of cash flow information | ||
| Cash paid for interest | $— | $— |
| Cash paid for taxes | $— | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.